Poster

OPN-6602, a dual EP300/CBP bromodomain inhibitor modulates androgen-driven transcription in mCRPC

Download PDF

Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cancer

Download PDF

Phase 1b/2a Study of PLX2853, a Small Molecule BET Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma

Download PDF

Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Download PDF

Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Download PDF

Phase 1b/2a Study of PLX51107, a Small Molecule BET Inhibitor, in Subjects with Advanced Hematological Malignancies and Solid Tumors

Download PDF

Resistance to BET inhibitors involves the Wnt/β-catenin Pathway in Uveal Melanoma

Download PDF

Response and Resistance to Bromodomain Inhibition in Acute Myeloid Leukemia

Download PDF

Broad Anti-Tumor Activity of a Novel BET Bromodomain Inhibitor

Download PDF

Efficacy and Mechanismof Action of the Novel Bromodomain Inhibitor, PLX51107, in B Cell Malignancies

Download PDF